Archemix Signs Aptamer Therapeutics Agreement with Lilly
Archemix also strengthens IP portfolio through patent license
Archemix Corp. announced that it has signed an agreement with Eli Lilly and Company (Lilly) regarding aptamer therapeutic R&D evaluation and access to intellectual property. The agreement enables Archemix to license certain intellectual property rights from Lilly and, in return, Lilly has an option to conduct R&D evaluation of aptamers for certain drug targets. Lilly also retains an option to enter into an exclusive license with Archemix for up to two of the aptamer targets.
“We are excited to enter into this collaboration with a company of the caliber of Lilly to consider pursuing drug targets where aptamer therapeutics may have unique advantages to treat diseases,” said Dr. Errol De Souza, President and Chief Executive Officer of Archemix. “This agreement also supports our strategy to further strengthen Archemix’s position of consolidating all of the significant intellectual property related to aptamer therapeutics.”
Other news from the department business & finance
